Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer? | GenomeWeb

Originally published Dec. 17.

By Turna Ray

Genentech said this week that it plans to request a hearing to maintain Avastin as a treatment option for metastatic breast cancer following the US Food and Drug Administration's recommendation to withdraw its approval of the drug for that indication.

The Roche subsidiary has 15 days from Dec. 16 to request the hearing, and noted that if the agency grants the request, "there is no set date for when this would occur."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.